Summary

Eligibility
for people ages up to 6 months (full criteria)
Location
at UCLA
Dates
study started
study ends around
Principal Investigator
by Sanjay Sinha, MD (ucla)

Description

Summary

Starlight Cardiovascular, Inc. is sponsoring a prospective, multi-center, study to evaluate safety and effectiveness of the Lifeline Ductus Arteriosus Stent System. The study device is a stent that is designed to maintain patency of the Ductus Arteriosus for children who need blood flow through that part of the heart.

Details

Starlight Cardiovascular, Inc. is sponsoring a prospective, multi-center, study to evaluate safety and effectiveness of the LifelineTM Ductus Arteriosus Stent System.

The purpose of the study is to determine whether the Ductus Arteriosus Stent System demonstrates safety and effectiveness for patients who require ductal patency and merits Food and Drug Administration (FDA) approval.

Keywords

Congenital Heart Disease, Congenital Heart Disease (CHD), Ductus Arteriosus Stent, pediatric stent, Lifeline Stent, Congenital Heart Defects, Stents

Eligibility

You can join if…

Open to people ages up to 6 months

  1. Parental or legal authorized representative provide consent for study enrollment
  2. Infants < 6 months of age
  3. Diagnosis of congenital heart defect with ductal-dependent pulmonary circulation requiring infusion of prostaglandins
  4. Requires ductus arteriosus stent diameters of 3.5mm or 4mm and stent lengths between 16mm and 28mm

You CAN'T join if...

  1. Active blood stream infection
  2. Active or history of endocarditis
  3. Body weight <2.5kg
  4. Gestational age <32 weeks at birth
  5. Complete heart block
  6. Total Anomalous Pulmonary Venous Return
  7. Anatomic variation judged to be inappropriate for ductal stenting per the treating interventionalist
  8. Presence of an aortopulmonary collateral that is expected to require unifocalization
  9. Non-confluent pulmonary arteries (i.e. isolated pulmonary artery of ductal origin) or bilateral patent ductus arteriosus (PDA)
  10. Pulmonary atresia with intact ventricular septum with RV-dependent coronary circulation
  11. Currently participating in an investigational drug study or another device study that would confound the study results
  12. Patient who is on extracorporeal membrane oxygenation (ECMO), ventricular assist device (VAD), or dialysis prior to ductal stenting procedure
  13. Major co-morbidities which, in the opinion of the investigator, would negatively alter expected 1-year survival (e.g., intracranial hemorrhage, renal failure, etc.)
  14. Patient who is undergoing another transcatheter procedure (e.g., atrial septostomy, aortic arch intervention, or right ventricular outflow tract intervention) during or within 24 hours prior to the ductus arteriosus stenting procedure
  15. Patient who, at the time of enrollment, is deemed not to be a candidate for eventual stage II palliation of single ventricle heart disease, complete surgical repair, nor transcatheter treatment with resultant biventricular circulation
  16. Patient who does not plan to return to the enrolling center or another participating center for stage II palliation, complete surgical repair, or definitive catheterization procedure
  17. Contraindications to peri-procedural anticoagulation
  18. Known to be non-responsive to aspirin or other antiplatelet therapies
  19. Known hypersensitivity or allergy to Nickel
  20. Known hypersensitivity to contrast media that cannot be adequately pre-medicated

Locations

  • UCLA Mattel Children's accepting new patients
    Los Angeles California 90095 United States
  • Leland Stanford Junior University accepting new patients
    Stanford California 94305 United States

Lead Scientist at University of California Health

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Starlight Cardiovascular Inc
ID
NCT07114718
Study Type
Interventional
Participants
Expecting 35 study participants
Last Updated